farglitazar has been researched along with Cardiotoxicity in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agostinucci, K; Colton, HM; Dunn, ME; Engle, SK; Gallacher, M; Gropp, KE; King, NM; Manfredi, TG; More, V; Powe, J; Rodriguez, LA; Serra, D; Shimpi, P; Vetter, FJ | 1 |
1 other study(ies) available for farglitazar and Cardiotoxicity
| Article | Year |
|---|---|
Serum Natriuretic Peptides as Differential Biomarkers Allowing for the Distinction between Physiologic and Pathologic Left Ventricular Hypertrophy.
Topics: Animals; Biomarkers; Cardiotoxicity; Diagnosis, Differential; Hypertrophy, Left Ventricular; Male; Natriuretic Peptides; Oxazoles; PPAR gamma; Rats, Sprague-Dawley; Swimming; Tyrosine; Ventricular Function, Left; Ventricular Remodeling | 2017 |